These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 31235963)

  • 1. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
    Chapuis AG; Egan DN; Bar M; Schmitt TM; McAfee MS; Paulson KG; Voillet V; Gottardo R; Ragnarsson GB; Bleakley M; Yeung CC; Muhlhauser P; Nguyen HN; Kropp LA; Castelli L; Wagener F; Hunter D; Lindberg M; Cohen K; Seese A; McElrath MJ; Duerkopp N; Gooley TA; Greenberg PD
    Nat Med; 2019 Jul; 25(7):1064-1072. PubMed ID: 31235963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
    Lulla PD; Naik S; Vasileiou S; Tzannou I; Watanabe A; Kuvalekar M; Lulla S; Carrum G; Ramos CA; Kamble R; Hill L; Randhawa J; Gottschalk S; Krance R; Wang T; Wu M; Robertson C; Gee AP; Chung B; Grilley B; Brenner MK; Heslop HE; Vera JF; Leen AM
    Blood; 2021 May; 137(19):2585-2597. PubMed ID: 33270816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
    Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
    Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study.
    Cho BS; Min GJ; Park S; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Am J Hematol; 2021 Jan; 96(1):98-109. PubMed ID: 32905642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
    Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
    Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
    Schneidawind C; Hagmaier V; Faul C; Kanz L; Bethge W; Schneidawind D
    Ann Hematol; 2018 Dec; 97(12):2491-2500. PubMed ID: 30066039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse.
    Luo XH; Poiret T; Liu Z; Meng Q; Nagchowdhury A; Ljungman P
    Front Immunol; 2022; 13():1027593. PubMed ID: 36824620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.
    Ido K; Nakamae M; Koh H; Okamura H; Nanno S; Nishimoto M; Takeoka Y; Hirose A; Nakashima Y; Hashimoto Y; Nakane T; Hino M; Nakamae H
    Transplantation; 2019 Oct; 103(10):2201-2210. PubMed ID: 30801534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.
    How J; Slade M; Vu K; DiPersio JF; Westervelt P; Uy GL; Abboud CN; Vij R; Schroeder MA; Fehniger TA; Romee R
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):648-653. PubMed ID: 28087457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Yang J; Cai Y; Jiang J; Wan L; Bai H; Zhu J; Li S; Wang C; Song X
    Ann Hematol; 2018 Mar; 97(3):497-507. PubMed ID: 29250743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.